Haemonetics Corporation (HAE)

Market Cap	3.75B
Revenue (ttm)	1.33B
Net Income (ttm)	114.89M
Shares Out	51.18M
EPS (ttm)	2.23
PE Ratio	32.83
Forward PE	15.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	763,164
Open	74.62
Previous Close	74.58
Day's Range	72.72 - 74.63
52-Week Range	70.74 - 97.97
Beta	0.30
Analysts	Buy
Price Target	107.50 (+46.78%)
Earnings Date	Oct 31, 2024

About HAE

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provi...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: May 9, 1991
• Employees: 3,657
• Stock Exchange: NYSE
• Ticker Symbol: HAE
• Website: https://www.haemonetics.com

Financial Performance

In 2023, Haemonetics's revenue was $1.31 billion, an increase of 12.01% compared to the previous year's $1.17 billion. Earnings were $117.56 million, an increase of 1.87%.

Analyst Forecast

According to 4 analysts, the average rating for HAE stock is "Buy." The 12-month stock price forecast is $107.5, which is an increase of 46.78% from the latest price.

Price Target

$107.5

(46.78% upside)

Analyst Consensus: Buy